Rohit Aggarwal, Professor and Myositis Fellowship Program Director at UPMC, shared a post on X:
“The most exciting news ever for myositis patients: a novel oral JAK1/TYK2 inhibitor (brepocitinib) shows positive Phase 3 results in dermatomyositis.
Honored to be part of the VALOR and NEJM – grateful to our patients, investigators, and Priovant.
FDA Approval soon.”
Title: A Phase 3 Trial of Brepocitinib in Dermatomyositis
Authors: Ruth Ann Vleugels, Julie Paik, Iazsmin Bauer Ventura, Aaron Mangold, Prateek Gandiga, Anna Haemel, Hector Chinoy, Yessar Hussain, Kumaraswamy Sivakumar, Zoltan Griger, Eun Bong Lee, Francisca Bozan, Chung-Yuan Hsu, Alisa Femia, Mazen Dimachkie, Michelle Min, Tahseen Mozaffar, Christina Charles-Schoeman, David Fernandez, Oluwakemi Onajin, Raquel Marques, Galina Marder, Floranne Ernste, Elena Schiopu, Jason Sluzevich, David Pearson, Stephen Lindsey, Michael Luggen, Michael Bubb, Erin Boh, Rashmi Maganti, Latisha Heinlen, Katharina Shaw, Matthew Cascino, Paul Mudd Jr., Jiri Vencovsky, Anthony Fernandez, David Fiorentino, Lisa Christopher-Stine, Victoria Werth, Rohit Aggarwal.
Other articles about Dermatomyositis on OncoDaily.